Medulloblastoma Therapy Reduction Following Surgery – Phase II

ACNS1422: A Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Protocol Description

The goal of this multi-center study by the Children’s Oncology Group is to find out if less chemotherapy and a reduced dose of radiation to the whole brain and spine can be given to children and young adults with average-risk medulloblastoma of the WNT-subgroup without increasing the risk of the tumor recurrence. This type of brain tumor grows in the very back of the brain in an area called the posterior fossa. Data has shown that a combination of chemotherapy and radiation achieve a high level of success in the WNT subgroup, however researchers believe that reducing certain elements of treatment may lower the potential for severe and long-term side effects.

Study Level: II

Eligibility Criteria

Subject to certain exclusion criteria, this study is enrolling patients ages 3 to 21 who have been newly diagnosed with a classic medulloblastoma of the WNT subgroup.
Males and Females: Ages 3 to 21 years


Therapy begins 36 days after the participant has had the tumor surgically removed, starting with 6 weeks of reduced-dose radiation therapy followed by a 4-week break. Treatment resumes with 7 cycles of maintenance chemotherapy at levels reduced from standard care that continue for 36 weeks for most participants.
Visits: Number of visits will vary based on participant response to protocol.
Duration: The treatment on this study takes about 12 months in most cases.

Status: Open to Enrollment

Source(s) of Support

Children’s Oncology Group (ACNS1422)
National Cancer Institute

Primary Investigator

James Felker, MD

Contact Information

For more information about the study or enrollment, please contact the UPMC Children’s Hospital of Pittsburgh Neuro-Oncology team, at: